Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$11.87 USD
+0.25 (2.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.82 -0.05 (-0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Iovance Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -444.04 | -395.89 | -342.25 | -259.58 | -197.56 |
Depreciation/Amortization & Depletion | 29.52 | 9.78 | 9.12 | 3.01 | -2.25 |
Net Change from Assets/Liabilities | -6.52 | -2.89 | 24.55 | 2.98 | 10.01 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 59.22 | 96.24 | 80.63 | 48.46 | 30.91 |
Net Cash From Operating Activities | -361.82 | -292.76 | -227.94 | -205.13 | -158.89 |
Property & Equipment | -22.29 | -20.43 | -37.57 | -46.79 | -6.92 |
Acquisition/ Disposition of Subsidiaries | -212.63 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 79.68 | 276.88 | 37.71 | -271.06 | 96.94 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -155.24 | 256.46 | 0.13 | -317.85 | 90.03 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 465.75 | 192.80 | 238.27 | 576.71 | 6.44 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -2.80 | -2.65 | 0.00 | -0.28 | -0.31 |
Net Cash from Financing Activities | 462.96 | 190.15 | 239.27 | 576.42 | 6.13 |
Effect of Exchange Rate Changes | -2.74 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -56.84 | 153.85 | 11.46 | 53.44 | -62.73 |
Cash at Beginning of Period | 238.16 | 84.31 | 72.85 | 19.42 | 82.15 |
Cash at End of Period | 181.32 | 238.16 | 84.31 | 72.85 | 19.42 |
Diluted Net EPS | -1.89 | -2.49 | -2.23 | -1.88 | -1.59 |
Fiscal Year End for Iovance Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -210.08 | -112.98 | -444.04 | -327.66 | -213.90 |
Depreciation/Amortization & Depletion | 20.77 | 7.57 | 29.52 | 21.54 | 13.54 |
Net Change from Assets/Liabilities | -71.26 | -32.55 | -6.52 | -18.41 | -24.30 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 39.86 | 15.67 | 59.22 | 46.68 | 30.89 |
Net Cash From Operating Activities | -220.71 | -122.28 | -361.82 | -277.85 | -193.77 |
Property & Equipment | -4.61 | -4.17 | -22.29 | -18.76 | -15.18 |
Acquisition/ Disposition of Subsidiaries | -52.57 | 0.00 | -212.63 | -212.89 | -209.51 |
Investments | -14.10 | -54.76 | 79.68 | 149.25 | 221.31 |
Other Investing Activities | 0.00 | -52.57 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -71.29 | -111.51 | -155.24 | -82.40 | -3.38 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 352.10 | 198.28 | 465.75 | 464.61 | 261.43 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -5.70 | -4.70 | -2.80 | -2.61 | -2.23 |
Net Cash from Financing Activities | 346.40 | 193.58 | 462.96 | 462.00 | 259.20 |
Effect of Exchange Rate Changes | -0.62 | -0.49 | -2.74 | -5.76 | -3.77 |
Net Change In Cash & Equivalents | 53.79 | -40.70 | -56.84 | 95.99 | 58.28 |
Cash at Beginning of Period | 181.32 | 181.32 | 238.16 | 238.16 | 238.16 |
Cash at End of Period | 235.11 | 140.62 | 181.32 | 334.15 | 296.44 |
Diluted Net EPS | -0.34 | -0.42 | -0.46 | -0.46 | -0.47 |